AP-HP, Avicenne Hospital, Department of Cardiology, UFR SMBH Paris 13 University, Bobigny, France.
Free Radic Res. 2011 Apr;45(4):379-88. doi: 10.3109/10715762.2010.532792. Epub 2010 Nov 10.
The aim was to determine (a) Ala-16Val-SOD2 dimorphisms; (b) allelic frequency and phenotype of a common Pro-Leu polymorphism in GPx1, in a cohort of patients with a cardiogenic shock (CS) due to dilated cardiomyopathy without acute coronary syndrome. Consecutive patients with de novo CS that worsened a dilated (DCM) or ischemic (ICM) cardiomyopathy. Congenital heart disease, pacemaker and other shock aetiologies were excluded. To determine oxidative stress (OS), this study evaluated lipid peroxidation, protein oxidation and erythrocyte GPx, SOD and catalase activities. Ala16Val-SOD2 (dbSNP: rs4880) and Pro198Leu-GPx1 (dbSNP: rs1050450) polymorphisms were studied by allelic discrimination using fluorogenic probes and the 5'nuclease (TaqMan) assay. Twenty-four patients (with ICM (n = 8) or DCM (n = 16), age = 57.5 ± 10.7 years, LVEF = 25.3 ± 8.5%, NT-proBNP levels = 8540 ± 1703 ng/L) were included during a 15 month follow-up. OS parameters were significantly higher in patients than in controls. Distribution of MnSOD genotypes was 47% Val/Val-variant, 29.5% Ala/Val and 23.5% Ala/Ala-variants. Severity of CS was more important in patients with Val/Val-variant and can be put in parallel with NT-proBNP levels (Val/Val-variant: 11 310 ± 3875 ng/L vs Ala/Ala-variant: 6486 ± 1375 ng/L and Ala/Val-variant: 6004 ± 2228 ng/L; p < 0.05) and hemodynamic support duration (144.6 vs Ala/Val-variant: 108.8 h and Ala/Ala-variant: 52.5 h; p < 0.05) with a positive correlation (Spearman rho = 0.72, p < 0.05). Moreover, Val/Val-variant significantly influenced the mortality (Spearman rho = 0.67, p < 0.05), but not the morbidity (p = 0.3). Distribution of GPx genotypes was 64% Pro/Pro, 18% Pro/Leu and 18% Leu/Leu. GPx-variants influenced neither GPx activities nor cardiac events. In conclusion, CS was associated with markers of increased OS. GPx polymorphism did not influence the GPx activity. Only the Val-encoding MnSOD allele was significantly correlated with the severity and prognosis of CS.
目的是确定(a)Ala-16Val-SOD2 二态性;(b)在一个因扩张型心肌病而导致心源性休克(CS)但无急性冠状动脉综合征的患者队列中,GPx1 中常见的 Pro-Leu 多态性的等位基因频率和表型。连续患有新发 CS 的患者,其病情恶化是由于扩张型(DCM)或缺血性(ICM)心肌病引起的。排除先天性心脏病、起搏器和其他休克病因。为了确定氧化应激(OS),本研究评估了脂质过氧化、蛋白质氧化和红细胞 GPx、SOD 和过氧化氢酶活性。使用荧光探针和 5'核酸酶(TaqMan)测定法,通过等位基因鉴别研究了 Ala16Val-SOD2(dbSNP:rs4880)和 Pro198Leu-GPx1(dbSNP:rs1050450)多态性。在 15 个月的随访期间,纳入了 24 名患者(ICM(n=8)或 DCM(n=16),年龄=57.5±10.7 岁,LVEF=25.3±8.5%,NT-proBNP 水平=8540±1703ng/L)。与对照组相比,患者的 OS 参数明显更高。MnSOD 基因型的分布为 47% Val/Val-变体、29.5% Ala/Val 和 23.5% Ala/Ala-变体。CS 严重程度在 Val/Val-变体患者中更为重要,与 NT-proBNP 水平(Val/Val-变体:11310±3875ng/L 与 Ala/Ala-变体:6486±1375ng/L 和 Ala/Val-变体:6004±2228ng/L;p<0.05)和血液动力学支持持续时间(144.6 与 Ala/Val-变体:108.8h 和 Ala/Ala-变体:52.5h;p<0.05)呈正相关(Spearman rho=0.72,p<0.05)。此外,Val/Val-变体显著影响死亡率(Spearman rho=0.67,p<0.05),但不影响发病率(p=0.3)。GPx 基因型的分布为 64% Pro/Pro、18% Pro/Leu 和 18% Leu/Leu。GPx 变体既不影响 GPx 活性,也不影响心脏事件。总之,CS 与 OS 增加的标志物有关。GPx 多态性不影响 GPx 活性。只有编码 MnSOD 的 Val 等位基因与 CS 的严重程度和预后显著相关。